PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK INHIBRX, INC.Inhibrx, Inc. • August 29th, 2023 • Biological products, (no disgnostic substances)
THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from INHIBRX, INC., a Delaware corporation (the “Company”), up to [•] shares of common stock, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
INDEMNIFICATION AGREEMENTIndemnification Agreement • July 28th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of [l], by and between INHIBRX, INC., a Delaware corporation (the “Company”), and [l] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
OPEN MARKET SALE AGREEMENTSMInhibrx, Inc. • September 3rd, 2021 • Biological products, (no disgnostic substances) • New York
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • July 28th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of July 15, 2020 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time, including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and INHIBRX, INC., a Delaware corporation with an office located at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 7th, 2022 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • California
This Third Amended and Restated Executive Employment Agreement (this “Agreement”) is effective as of January 1, 2023 (the “Effective Date”) by and between Inhibrx, Inc., a Delaware corporation (the “Company”), and Mark Lappe (“Executive”).
RESTRICTED STOCK AGREEMENT INHIBRX, INC.Restricted Stock Agreement • January 7th, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made as of the [ ] day of [ ], 20[ ] (the “Grant Date”), between Inhibrx, Inc. (the “Company”), a Delaware corporation, and [ ] (the “Participant”).
Option and License AgreementOption and License Agreement • July 28th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This Option and License Agreement (this “Agreement”), effective as of June 9, 2020 (the “Effective Date”), is entered into by and between Inhibrx, Inc., a Delaware corporation (“Inhibrx”), and bluebird bio, Inc., a Delaware corporation (“Licensee”). Inhibrx and Licensee are referred to individually as a “Party” and collectively as the “Parties.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 29th, 2023 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of August 28, 2023, is made by and among Inhibrx, Inc., a Delaware corporation (the “Company”), and the Purchasers listed on Schedule 1 hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”).
TECHNICAL SERVICES AGREEMENTTechnical Services Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This Technical Services Agreement (“Agreement”) is made and entered into as of the 6 day of October, 2018 (“Effective Date”) by and between Hangzhou Just Biotherapeutics Co., Ltd., a limited liability company having offices at 11/F, Building 5, No.2 Ke Ji Yuan Road, Hangzhou Eco-Tech Development Area, Hangzhou, China, 310018 (“Just”) and Inhibrx, Inc. (“Inhibrx”), a Delaware corporation with an address at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037. Just and Inhibrx may be referred to herein each, individually, as a “Party” or, collectively, as the “Parties”.
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of December 22, 2016 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 thereof from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and Inhibrx, LP, a Delaware limited partnership, Inhibrx 101, LP, a Delaware limited partnership, Inhibrx 104, LP, a Delaware limited partnership, INBRX 105, LP, a Delaware limited partnership, INBRX 106, LP, a Delaware limited partnership, INBRX 107, LP, a Delaware limited partnership, INBRX 108, LP, a Delaware limited partnership, INBRX 109, LP, a Delaware limited partnership, INBRX 110, LP, a Delaware limited partnership, INBRX 111, LP, a Delaware li
INHIBRX, INC. AMENDMENT TO CONVERTIBLE PROMISSORY NOTEPurchase Agreement • July 28th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This AMENDMENT (the “Amendment”) to that certain Convertible Promissory Note listed on Schedule A hereto (the “Note”) issued pursuant to the terms of that certain Note Purchase Agreement by and among the Inhibrx, Inc., a Delaware corporation (the “Company”) and DRAGSA 50 LLC (the “Investor”), dated as of May 20, 2019 (the “Purchase Agreement”), is entered into as of April 6, 2020, by and between the Company and the Investor. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Note.
FIRST AMENDMENT, WAIVER AND CONSENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS FIRST AMENDMENT, WAIVER AND CONSENT to the Loan and Security Agreement (this “Amendment”) is entered into as of August 15, 2016 (the “First Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and ”), and Inhibrx, LP, a Delaware limited partnership, Inhibrx 101, LP, a Delaware limited partnership, Inhibrx 104, LP, a Delaware limited partnership, INBRX 105, LP, a Delaware limited partnership, INBRX 106, LP, a Delaware limited partnership, INBRX 107, LP, a Delaware limited partnership, INBRX 108, LP, a Delaware limited partnership, INBRX 109, LP, a Delaware limited partnership, INBRX 1
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...License Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (“Agreement”) is made and entered into as of the 28th day of February 2018, Pacific Standard time (the “Effective Date”) by and between Elpiscience Biopharmaceuticals, Inc., a Cayman Islands company having offices at Offices of Corporate Filing Services Ltd., 3rd Floor, Harbour Centre, George Town, P.O. Box 613, Grand Cayman KY1-1107, Cayman Islands (“Elpiscience”) and Inbrx105 LP (“Inhibrx”), a Delaware limited partnership with an address at 11099 North Torrey Pines Road, Suite 280, La Jolla, CA 92037. Elpiscience and Inhibrx are each referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENTLicense Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (“Agreement”) is made and entered into as of the 28th day of February 2018, Pacific Standard time (the “Effective Date”) by and between Elpiscience Biopharmaceuticals, Inc., a Cayman Islands company having offices at Offices of Corporate Filing Services Ltd., 3rd Floor, Harbour Centre, George Town, P.O. Box 613, Grand Cayman KY1-1107, Cayman Islands (“Elpiscience”) and Inbrx105 LP (“Inhibrx”), a Delaware limited partnership with an address at 11099 North Torrey Pines Road, Suite 280, La Jolla, CA 92037. Elpiscience and Inhibrx are each referred to herein individually as a “Party” and collectively as the “Parties.”
●] SHARES INHIBRX, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • August 12th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...License Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (this “Agreement”) is made effective e as of July 1, 2013 (“Effective Date”) by and between INBRX 103, LLC, a limited liability company with an address at 11099 North Torrey Pines Road, Suite 130, La Jolla, CA 92037 (“Inhibrx”), and Celgene Corporation a Delaware corporation with an address at 86 Morris Avenue, Summit, NJ 07901 (“Licensee”). Inhibrx and Licensee each may be referred to herein individually as a “Party” and together as the “Parties.”
FIRST AMENDMENT TO LEASELease • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of May 21, 2019, by and between HCP TPSP, LLC, a Delaware limited liability company (“Landlord”), and INHIBRX, INC., a Delaware corporation (“Tenant”).
CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENTConsent And • January 7th, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS CONSENT AND THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of April 30, 2018 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 thereof from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), Inhibrx, LP, a Delaware limited partnership, Inhibrx 101, LP, a Delaware limited partnership, Inhibrx 104, LP, a Delaware limited partnership, INBRX 105, LP, a Delaware limited partnership, INBRX 106, LP, a Delaware limited partnership, INBRX 107, LP, a Delaware limited partnership, INBRX 108, LP, a Delaware limited partnership, INBRX 109, LP, a Delaware limited partnership, INBRX 110, LP, a Delaware limited partnership, INBRX 111, LP, a Delawar
FIRST AMENDMENT TO OPTION AGREEMENTOption Agreement • August 20th, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT (this “First Amendment”) to the Option Agreement, dated May 29, 2019, (the “Agreement”) by and between Chiesi Farmaceutici S.p.A., a corporation existing under the laws of Italy having its registered office at Via Palermo 26/A, 43122 Parma, Italy (“Chiesi”), and InhibRx, Inc., a corporation existing under the laws of the State of Delaware, having its principal office at 11025 N. Torrey Pines Rd, Suite 200 La Jolla, CA 92037 (“InhibRx”), is made effective as of August 19, 2019 (the “First Amendment Effective Date”).
CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENTLicense Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (“Agreement”) is made and entered into as of the 21st day of June 2017, New York Time (the “Effective Date”) by and between Hangzhou Just Biotherapeutics Co., Ltd., a limited liability company having offices at 11/F, Building 5, No.2 Ke Ji Yuan Road, Hangzhou Eco-Tech Development Area, Hangzhou, China, 310018 (“Just”) and Inbrx109 LP (“Inhibrx”), a Delaware limited partnership with an address at 11099 North Torrey Pines Road, Suite 280, La Jolla, CA 92037. Just and Inhibrx are each referred to herein individually as a “Party” and collectively as the “Parties.”
AGREEMENT RELATING TO THE PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK AND SECURITIES PURCHASE AGREEMENTPurchase Common Stock and Securities Purchase Agreement • January 23rd, 2024 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
THIS AGREEMENT (the “Agreement”), dated as of January 22, 2024, amends the Pre-Funded Warrant to Purchase Common Stock, dated August 31, 2023, issued by Inhibrx, Inc., a Delaware corporation (the “Company”), to [●] (the “Holder”) and specifies certain registration and other rights of the Holder.
THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 21st, 2021 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of June 18, 2021 (the “Third Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and INHIBRX, INC., a Delaware corporation with an office located at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Borrower”).
SEPARATION AND DISTRIBUTION AGREEMENT BY AND AMONG INHIBRX, INC., IBEX SPINCO, INC., AND, SOLELY WITH RESPECT TO SECTION 2.7(b), SECTION 2.10, SECTION 3.3, SECTION 4.2, SECTION 4.3, SECTION 4.7, SECTION 5.1, SECTION 6.6(i), SECTION 8.3, SECTION 8.6,...Separation and Distribution Agreement • January 23rd, 2024 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This SEPARATION AND DISTRIBUTION AGREEMENT (this “Agreement”), dated as of January 22, 2024, is entered into by and among Inhibrx, Inc., a Delaware corporation (together with its successor entities, the “Company”), Ibex SpinCo, Inc., a Delaware corporation and a wholly owned Subsidiary of the Company (“SpinCo” and, together with the Company, the “Parties” and each a “Party”), and, solely with respect to Section 2.7(b), Section 2.10, Section 3.3, Section 4.2, Section 4.3, Section 4.7, Section 5.1, Section 6.6(i), Section 8.3, Section 8.6, Section 8.7 and Section 8.8, Aventis Inc., a Pennsylvania corporation (“Parent”).
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...License Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This License Agreement (this “Agreement”), effective as of December 20, 2018 (the “Effective Date”), is entered into by and between Inhibrx, Inc., a Delaware corporation (“Inhibrx”), and bluebird bio, Inc., a Delaware corporation (“Licensee”). Inhibrx and Licensee are referred to individually as a “Party” and collectively as the “Parties.”
TERMINATION AGREEMENTTermination Agreement • February 28th, 2024 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
This Termination Agreement (this “Termination Agreement”), effective as of February 26, 2024 (the “Effective Date”), is made by and between Inhibrx, Inc. (formerly known as Inbrx105 LP), a Delaware corporation located at 11025 N. Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Inhibrx”), and Elpiscience Biopharmaceuticals, Inc., a Cayman Islands company having offices at Offices of Corporate Filing Services Ltd., 3rd Floor, Harbour Centre, George Town, P.O. Box 613, Grand Cayman KYI-1107, Cayman Islands (“Elpiscience,” and together with Inhibrx, the “Parties,” and each, a “Party”).
CONFIDENTIAL TREATMENT REQUESTED AMENDED AND RESTATED MASTER SERVICES AGREEMENTMaster Services Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
This Amended and Restated Master Services Agreement (“Agreement”) is dated August 28, 2018 (the “Restated Effective Date”) and is between Inhibrx, Inc. (“Client”) and WuXi Biologics (Hong Kong) Limited (“Provider”).
FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • February 22nd, 2022 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS FOURTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of February 18, 2022 (the “Fourth Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and INHIBRX, INC., a Delaware corporation with an office located at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Borrower”).
RESTRICTED STOCK AGREEMENT INHIBRX, INC.Restricted Stock Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made as of the [ ] day of [ ], 20[ ] (the “Grant Date”), between Inhibrx, Inc. (the “Company”), a Delaware corporation, and [ ] (the “Participant”).
CONFIDENTIAL TREATMENT REQUESTED License AgreementConfidential Treatment Requested • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This License Agreement (this “Agreement”), effective as of December 20, 2018 (the “Effective Date”), is entered into by and between Inhibrx, Inc., a Delaware corporation (“Inhibrx”), and bluebird bio, Inc., a Delaware corporation (“Licensee”). Inhibrx and Licensee are referred to individually as a “Party” and collectively as the “Parties.”
ContractInhibrx, Inc. • July 28th, 2020 • Biological products, (no disgnostic substances) • New York
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...License Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (“Agreement”) is made and entered into as of the 21st day of June 2017, New York Time (the “Effective Date”) by and between Hangzhou Just Biotherapeutics Co., Ltd., a limited liability company having offices at 11/F, Building 5, No.2 Ke Ji Yuan Road, Hangzhou Eco-Tech Development Area, Hangzhou, China, 310018 (“Just”) and Inbrx109 LP (“Inhibrx”), a Delaware limited partnership with an address at 11099 North Torrey Pines Road, Suite 280, La Jolla, CA 92037. Just and Inhibrx are each referred to herein individually as a “Party” and collectively as the “Parties.”
SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 4th, 2022 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS SIXTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of October 3, 2022 (the “Sixth Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and INHIBRX, INC., a Delaware corporation with an office located at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Borrower”).
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...Master Services Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
This Amended and Restated Master Services Agreement (“Agreement”) is dated August 28, 2018 (the “Restated Effective Date”) and is between Inhibrx, Inc. (“Client”) and WuXi Biologics (Hong Kong) Limited (“Provider”).
CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENTLicense Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (this “Agreement”) is made effective e as of July 1, 2013 (“Effective Date”) by and between INBRX 103, LLC, a limited liability company with an address at 11099 North Torrey Pines Road, Suite 130, La Jolla, CA 92037 (“Inhibrx”), and Celgene Corporation a Delaware corporation with an address at 86 Morris Avenue, Summit, NJ 07901 (“Licensee”). Inhibrx and Licensee each may be referred to herein individually as a “Party” and together as the “Parties.”
FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 16th, 2022 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS FIFTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of June 15, 2022 (the “Fifth Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and INHIBRX, INC., a Delaware corporation with an office located at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Borrower”).
